COST-BENEFIT OF INTEGRATING CRYPTOCOCCAL ANTIGEN SCREENING AND PREEMPTIVE TREATMENT INTO ROUTINE HIV CARE Radha Rajasingham, David Meya, Melissa Rolfes,

Slides:

Advertisements

Similar presentations

CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):

Advertisements

Using longitudinal, population-based HIV surveillance to measure the real-world impacts of ART scale-up in KwaZulu- Natal, South Africa Frank Tanser Presentation.

Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,

The South African Cryptococcal Screening Program: Program update XIX international AIDS Conference Washington United States 24 th July 2012 Dr. Samuel.

The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.

Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.

Scaling up Prevention of Mother to Child Transmission of HIV (PMTCT): What Will it Take to Eliminate MTCT? Jessica Rodrigues Presentation for UNICEF Written.

Late-outcomes of TB-IRIS William Worodria, MBChB, MMed, PhD Senior EDCTP Fellow Infectious Disease Institute, Kampala, Uganda Mulago Hospital & Complex,

Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

MS&E 220 Project Yuan Xiang Chew, Elizabeth A Hastings, Morris Jinhui Zhang Probabilistic Analysis of Cervical Cancer Screening and Vaccination.

Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

U. S. Senate Briefing World TB Day Celine Gounder, MD, ScM Center for TB Research, Johns Hopkins University Director for Delivery, CREATE On behalf of.

Miriam Nuño Harvard School of Public Health, USA Gerardo Chowell Los Alamos National Laboratory, USA Abba Gumel University of Manitoba, Canada AIMS/DIMACS/SACEMA.

Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.

Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.

Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.

Module 7: Malaria and HIV/AIDS Palliative Care for People Living with HIV/AIDS.

Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,

Cryptococcal IRIS: Pathogenesis & Pearls for Clinical Management

Cryptococcal Screening- Laboratory perspective and considerations in South Africa and sub-Saharan Africa Prof W. Stevens Head Department Molecular Medicine.

HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.

Screen-and-Treat A new strategy to prevent cryptococcal deaths.

Iman Wanis, Cushla Coffey, Shaffiq Essajee, and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 COSTING.

Iman Wanis and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011 What is the reality in the field? Survey.

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Cost-Effectiveness of a Lateral-Flow Urine Lipoarabinomannan Test for TB diagnosis in HIV-infected South African Adults Di Sun1; Susan Dorman2,3,4; Maunank.

Evaluation of a Novel Point of Care Cryptococcal Antigen (CRAG) Test on Serum, Plasma and Urine from Patients with HIV-associated Cryptococcal Meningitis.

IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.

Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.

Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.

Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University Health Economics and Epidemiology Research Office July.

Edward Mills PhD, Associate Professor, Faculty of Health Sciences University of Ottawa AIDS Mortality Among Men in Africa: An overview of the evidence.

HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4

Press Briefing: Office of the Vice Chancellor MUK 6 th September 2010 The Infectious Diseases Institute Care and Research Initiatives Dr Alex G Coutinho.

Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.

TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.

Cryptococcal Antigen Screening in Uganda David R Boulware MD MPH Radha Rajasingham MD David B Meya MMed Infectious Disease Institute Makerere University.

Complex OIs of the CNS David R Boulware MD, MPH, CTropMed Lois & Richard King Distinguished Assoc. Professor University of Minnesota

Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.

A Call to Action Children – The missing face of AIDS.

INVESTING IN COMMUNITY SYSTEMS TO SUPPORT LIFELONG ART INITIATED IN MATERNAL & CHILD HEALTH SETTINGS Dr. Chewe Luo MD, PhD, FRCP UNICEF PROGRAM DIVISION.

Date of download: 5/31/2016 From: Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med. 2008;148(12): doi: /

Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

1 NAME: TITLE:DATE:. 2 “One stop shop” for TB and HIV services improved initiation of antiretroviral therapy (ART) for co-infected patients in Eastern.

Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,

The Changing Face of Advanced Disease

Trends in maternal deaths in HIV-infected women, on a background of changing HIV management guidelines in South Africa: 1997 to ,2,3CN Mnyani, 1EJ.

Amir Shroufi Medical Coordinator MSF South Africa

ART was initiated when indicated by WHO and national guidelines

Presented to the AIDS 2016 Conference

Earlier treatment and lower mortality in infants Initiating ART at

Participants 18year old+

CD4+ T-lymphocyte count <100 cells/µl

Implementing CRAG Screening among HIV Patients Initiating ART in Rural HIV Clinics with Regular Absence of CD4 Testing Services in Tanzania Gladys Mbwanji.

World Health Organization

Patients w/AIDS-defining illness

Abstract no. WEPDB0104 JC Mogambery1, H Dawood2, D Wilson3, A Moodley4

Meningitis Surveillance and investigation of causes of altered mental status among Kamuzu Central Hospital admissions, Lilongwe, Malawi Charles Kyriakos.

Cryptococcal Antigen (CrAg) Essential In Vitro Diagnostic Device

CommCare as a Tool to Reduce Loss to Follow Up

Cryptococcosis: Treatment outcome

CrAg titers- To know or not to know

Knowing your epidemic and knowing your response – maximising routinely collected data to measure and monitor HIV epidemics in sub-Saharan Africa Monitoring.

Cryptococcal Immune Reconstitution Inflammatory Syndrome

Cryptococcal Immune Reconstitution Inflammatory Syndrome

Cryptococcosis: Epidemiology of cryptococcal disease

Cryptococcosis: Treatment outcome

TB Screening and Differentiated Service Delivery: State of the Art

Presentation transcript:

COST-BENEFIT OF INTEGRATING CRYPTOCOCCAL ANTIGEN SCREENING AND PREEMPTIVE TREATMENT INTO ROUTINE HIV CARE Radha Rajasingham, David Meya, Melissa Rolfes, Kate Birkenkamp, David R Boulware Presented by: Radha Rajasingham, MD July 23, 2012

Background Cryptococcal Meningitis causes ~20-25% of AIDS- related attributable mortality in sub-Saharan Africa Cryptococcal Antigen (CrAg) can be detected >3 weeks before onset of symptoms Asymptomatic CrAg+ persons have a high risk of subsequent CM and death, despite ART. A new CrAg point of care lateral flow assay (LFA) is available with excellent sensitivity and specificity

Methods We assessed the cost-benefit of targeted CRAG screening for patients with CD4<100 using the LFA ($2.50/screen) coupled with preemptive fluconazole therapy for CRAG+ persons entering HIV care in sub-Saharan Africa CRAG LFA Cost Components CRAG LFA Assay $ Lab Supplies $0.05 One pipette tip, one Eppendorf tube Labor $0.25 Overhead $0.20 LFA can be shipped/stored at room temperature

Performed CRAG screening at the Infectious Disease Institute in Kampala Uganda between 2004 and 2007 CRAG latex agglutination was $16.75 per test Among HIV+ with a CD4<100, 8.8% (26/295) had asymptomatic/subclinical cryptococcal antigenemia 21 were treated with fluconazole ( mg x 2-4 weeks), 30- month survival was 71% 5 were not treated with fluconazole, and all died within 2 months of starting ART Clinical Infectious Diseases 2010; 51:

Cost-Effectiveness Analysis Among CD4<100, the number needed to screen in order to detect one CRAG+ was 11.3 (95% CI: ) NNS = 1 / prevalence NNS = 1 / The number needed to be screened and treated to prevent one death was 15.9 people NNT life-saved = 1 / (prevalence * survival) NNT life-saved = 1 / (0.088 * 0.71)

Based on $16.75 CRAG, this translates to: $190 (95% CI: $132-$286) to detect one asymptomatic person with cryptococcal antigenemia $266 (95% CI: $185 to $402) to save one person’s life with preemptive fluconazole Assuming an average increase in life expectancy of 18 years for a 30yo Ugandan initiating ART with a CD4<100,* this is $14.77 per DALY saved * Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:

CRAG Lateral Flow Assay (LFA) Immunochromatographic LFA test FDA approved July 2011

Using the same assumptions Among HIV+ with CD4<100 cells/µL with CRAG+ prevalence of 8.8%: To detect one CRAG+, the number need to screen was 11.3 (95% CI: ) To prevent one death, 15.9 people would need to be screened and treated

Based on CRAG LFA cost of $2.50: The cost of detecting one person with subclinical antigenemia with the LFA is $28.37 (95% CI: $20 to $43) The cost of saving one life is $39.73 (95% CI: $28 to $60) Assuming an average increase in life expectancy of 18 years for a 30yo Ugandan initiating ART with a CD4<100,* this is $2.21 per DALY saved * Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:

Prevalence of asymptomatic antigenemia with corresponding cost per life saved based on LFA cost of $2.50 per test

CrAg Latex Agglutination CrAg Lateral Flow Assay No CrAg Screening

Conversely, the cost of hospitalization and 14 days of amphotericin for treatment of cryptococcal meningitis is: $425 per episode in Uganda $2883 per episode in South Africa Thus for the treatment costs of 1 cryptococcal meningitis episode, one could perform CRAG LFA screening on: 170 persons in Uganda 1153 persons in South Africa Above a CRAG+ prevalence of 1%, pre-ART CRAG screening is C OST S AVING compared to the cost of amphotericin and CM treatment CRAG Screening is Cost Saving

Conclusions Targeted CRAG screening and preemptive fluconazole therapy is cost-saving to health care systems and should be integrated into routine HIV care for persons with CD4<100. Better understanding of the implementation science is needed to determine how best to scale up CRAG screening and define optimal treatment.